MUMBAI, April 23 (Reuters) - Indian biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its $600 million research and development arm, Syngene, it said on Thursday.
The company plans to sell 22 million shares, including an overallotment, it said in a statement, after the prospectus was filed with India's market regulator.
Also read: Roku Expects IPO to Raise More Than $200 Million
Read more
